drugset / Trial / NCT02650791

Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study

NCT02650791

Phase 3 Completed 100 enrolled Ottawa Hospital Research Institute
RandomizedParallel-groupOpen-labelOther

Summary

It is hypothesized that a strategy using prophylactic oral Tranexamic Acid (TXA) with therapeutic platelet transfusions is safe and effective compared to prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (who are at risk for bleeding).

Timeline

Start
2016-10
Primary completion
2019-06
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1 g Oral